Introduction to the usage and dosage of cartegravir injection

Cabotegravir injection (Cabotegravir), as the first long-acting injectable preparation drug approved by the U.S. Food and Drug Administration (FDA) for HIV pre-exposure prophylaxis, provides a new option for preventing the spread of HIV-1 virus. It is particularly suitable for adults and teenagers who weigh at least 35kg and effectively reduces the risk of contracting the HIV-1 virus through sexual intercourse by blocking the integrase enzyme required for HIV-1 self-replication.

In terms of usage and dosage, the use of canegravir injection needs to follow strict guidelines. First, a starting dose of 600mg is given via injection into the gluteal muscle. This dose requires two consecutive injections spaced 1 months apart. Of note, the timing of the second injection can fluctuate up to 7days above or below the scheduled time, providing some flexibility for patients in their dosing. After completing these two initial injections, patients will enter a subsequent maintenance treatment phase, with a dose of 600 mg per month, but the frequency of injections is reduced to once every 2 months. In addition, to ensure the effectiveness of the drug, the first injection should be given on or within 3 days after the last day of oral induction dose, and the timing of each injection can fluctuate up to 7 days up or down the planned time based on the patient's specific circumstances.

In terms of dosage adjustment, although the dosage of cartegravir injection is relatively fixed, patients still need to pay close attention to their own conditions during use and make necessary adjustments under the guidance of a doctor. For example, if a patient experiences any discomfort or side effects during medication, the doctor may adjust the dosage or frequency of medication based on the patient's specific condition.

When using cartegravir injection, patients should also pay attention to the following points. First, a negative HIV test is required before starting treatment to prevent the development of drug resistance. Secondly, patients should use the medicine strictly according to the doctor's instructions and do not adjust the dosage or stop the medicine on their own. In addition, patients should undergo regular physical examinations during the medication period and monitor changes in liver and kidney function, blood routine and other indicators to ensure the efficacy and safety of the medication. At the same time, patients also need to pay close attention to the side effects and adverse reactions of drugs. If any abnormality occurs, they should seek medical treatment in time and inform the doctor. In short, the usage and dosage of cartegravir injection needs to follow strict instructions and be used under the guidance of a doctor to ensure the efficacy and safety of the drug.

Reference link:https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212887s007lbl.pdf